Interferon therapy of chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B (CHB) arises from the host immune system's failure to control hepatitis B virus (HBV) replication.
• Interferon-alfa (IFN-α) therapy converts CHB to inactive infection in 20-30% of patients, offering post-treatment benefits like HBsAg clearance.

Purpose of the Study:

• To explore the multifaceted antiviral, antiproliferative, and immunomodulatory mechanisms of IFN-α in CHB.
• To investigate factors influencing IFN-α susceptibility, including viral heterogeneity and host genetic polymorphisms.
• To emphasize the need for a systems medicine approach integrating molecular and clinical data for improved CHB therapy.

Main Methods:

• Analysis of IFN-α's molecular targets, including IFN-stimulated genes, HBV replication intermediates, and covalently closed circular DNA (cccDNA).
• Evaluation of IFN-α's impact on innate and adaptive immune responses.
• Discussion of quantitative monitoring of serum HBV DNA and HBsAg for personalized treatment strategies.

Main Results:

• IFN-α exhibits diverse activities, including blocking HBV core particle formation, degrading pregenomic RNA, and modulating cccDNA epigenetic regulation.
• IFN-α enhances antiviral defense pathways and modulates both innate and adaptive immunity.
• On-treatment monitoring of HBV DNA and HBsAg aids in tailoring therapy and improving cost-effectiveness.

Conclusions:

• A comprehensive understanding of IFN-α's complex actions is crucial for refining current CHB treatments and developing novel therapeutic strategies.
• Personalized treatment approaches, informed by molecular and clinical data, are essential for optimizing antiviral therapy in CHB.
• Systems medicine approaches are mandatory for advancing antiviral therapy in CHB.